TARS
Price
$75.23
Change
-$0.50 (-0.66%)
Updated
Jan 14 closing price
Capitalization
3.19B
60 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$41.58
Change
+$1.22 (+3.02%)
Updated
Jan 14 closing price
Capitalization
3.21B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

TARS vs XENE

Header iconTARS vs XENE Comparison
Open Charts TARS vs XENEBanner chart's image
Tarsus Pharmaceuticals
Price$75.23
Change-$0.50 (-0.66%)
Volume$289.54K
Capitalization3.19B
Xenon Pharmaceuticals
Price$41.58
Change+$1.22 (+3.02%)
Volume$1.2M
Capitalization3.21B
TARS vs XENE Comparison Chart in %
View a ticker or compare two or three
VS
TARS vs. XENE commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TARS is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (TARS: $75.23 vs. XENE: $41.58)
Brand notoriety: TARS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: TARS: 53% vs. XENE: 137%
Market capitalization -- TARS: $3.19B vs. XENE: $3.21B
TARS [@Biotechnology] is valued at $3.19B. XENE’s [@Biotechnology] market capitalization is $3.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TARS’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • TARS’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, TARS is a better buy in the long-term than XENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TARS’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • TARS’s TA Score: 4 bullish, 5 bearish.
  • XENE’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, TARS is a better buy in the short-term than XENE.

Price Growth

TARS (@Biotechnology) experienced а -3.65% price change this week, while XENE (@Biotechnology) price change was -1.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

TARS is expected to report earnings on Mar 16, 2026.

XENE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.21B) and TARS($3.19B) have the same market capitalization . XENE (-7.229) and TARS (-7.511) have similar YTD gains . TARS has higher annual earnings (EBITDA): -70.9M vs. XENE (-338.18M). XENE has more cash in the bank: 462M vs. TARS (402M). XENE has less debt than TARS: XENE (8.33M) vs TARS (72.4M). TARS has higher revenues than XENE: TARS (366M) vs XENE (7.5M).
TARSXENETARS / XENE
Capitalization3.19B3.21B99%
EBITDA-70.9M-338.18M21%
Gain YTD-7.511-7.229104%
P/E RatioN/AN/A-
Revenue366M7.5M4,880%
Total Cash402M462M87%
Total Debt72.4M8.33M869%
FUNDAMENTALS RATINGS
XENE: Fundamental Ratings
XENE
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
37
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
53
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
TARSXENE
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 16 days ago
82%
Bullish Trend 24 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
TARS
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EVUYX20.01N/A
N/A
Allspring Util and Telecomms Inst
PEXMX36.76-0.02
-0.05%
T. Rowe Price Extended Equity Market Idx
SGLIX32.04-0.07
-0.22%
SGI Global Equity I
RGDTX11.42-0.04
-0.35%
Russell Inv Global Equity M
APGAX99.24-0.55
-0.55%
AB Large Cap Growth A

TARS and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARS has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARS
1D Price
Change %
TARS100%
+0.26%
XENE - TARS
39%
Loosely correlated
-2.11%
MIRM - TARS
39%
Loosely correlated
+1.05%
MDGL - TARS
38%
Loosely correlated
-3.26%
XERS - TARS
36%
Loosely correlated
-2.03%
RYTM - TARS
36%
Loosely correlated
+2.77%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+3.02%
IDYA - XENE
57%
Loosely correlated
+5.53%
NUVL - XENE
57%
Loosely correlated
+6.59%
SGMO - XENE
53%
Loosely correlated
-3.43%
XNCR - XENE
52%
Loosely correlated
+3.66%
NRIX - XENE
51%
Loosely correlated
+0.58%
More